Maarten de Château

OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.

Beactica Therapeutics AB operates as a drug discovery company, utilizing its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. The firm's services include fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate analysis, competition analysis, and antibody interaction analysis. The company was founded by Per K?llblad and Ulla Helena Danielson in 2006 and is headquartered in Uppsala, Sweden.

AddBIO AB provides bone implant technology solutions. It offers Zolidd, a bioactive nanolayer with a bone strengthening drug. The firm's Zolidd is used in the areas of dental and trauma implants. It also offers Zolidiser, a machine to add bone-strengthening drugs to implants. The company was founded by Per Aspenberg and Trine Vikinge in 2008 and is headquartered in Linköping, Sweden.

Cormorant Pharmaceuticals AB provides biopharmaceutical products.The company was founded by Maarten de Chateau and Urban Paulsson in 2010 and is headquartered in Solna, Sweden.

Atrogi AB engages in research and development & sells type 2 diabetes (T2D) with minimal side effects. The company was founded by Tore Bengtsson and Andreas Bhagwani in 2013 and is headquartered in Solna, Sweden.

Sixera Pharma AB conducts activities within research, development, and commercialization of pharmaceuticals. It develops treatment for Netherton syndrome. The company was founded by Jean Nordstrom on August 21, 2012 and is headquartered in Göteborg, Sweden.